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Diagnosing Diabetes With Glucose
Criteria: Worshipping a False God
I
n this issue of Diabetes Care, Dr. David
Sacks has nicely delineated the pros
and cons of the measurements of glu-
cose concentrations and A1C levels and
the resulting effects on using each to di-
agnose diabetes (1). With the continued
improvement in A1C assays, the balance
seemstoincreasinglyfavorusingA1Clev-
els. This commentary will examine an is-
suethathasreceivedscantattentioninthe
past,i.e.,whatistheactualevidenceupon
which the current glucose criteria for di-
agnosing diabetes mellitus is based?
Glucose concentrations in almost all
populations (except those with very high
prevalencesofdiabetes,e,g.,PimaIndians),
are distributed unimodally with a
rightward skew (2,3), making the choice
of a diagnostic value for diabetes arbi-
trary. If glucose concentrations are log-
transformed to minimize the rightward
skewness, a bimodal distribution has
been noted (4–8). However, cutoff values
deﬁning the two distributions have
ranged from 200–307 mg/dL, mostly de-
pendingontheagesofthepopulationsur-
veyed (3–8).
Priorto1979,atleastsixdifferentsets
of criteria diagnosed diabetes (9). In
1979, the National Diabetes Data Group
(NDDG) resolved this issue by establish-
ing one set of criteria (10). They selected
these criteria based on glucose concentra-
tionsthatallegedlypredictedthedevelop-
ment of diabetic retinopathy, a speciﬁc
microvascular complication of diabetes.
Three prospective studies (11–13) were
available to the NDDG on which to base
their decision. A total of 1,213 patients
were followed for 3 to 8 years after oral
glucose tolerance tests (OGTTs), 77 of
whom developed retinopathy. There
was no further evaluation of their gly-
cemic status after the original OGTT,
although it was very likely that the 77
people who developed retinopathy in the
studies used by the NDDG to establish
the diagnostic criteria had increasing gly-
cemia in the years between the test and
the identiﬁcation of retinopathy. How-
ever, on the basis of these 77 individuals,
the NDDG selected a fasting plasma glu-
cose (FPG) concentration of $140 mg/dL
or a 2-h value after 75 g oral glucose of
$200 mg/dL to diagnose diabetes. Thus,
the“goldstandard”2-hvalueonanOGTT
fordiagnosingdiabetesrestsonfewerthan
100 individuals whose glycemic status
was unknown for years prior to the devel-
opment of retinopathy. A description of
the three studies used for their decision
is available (14).
In the mid-1990s, the American Di-
abetes Association (ADA) convened an
Expert Committee (15) to reexamine the
diagnosis of diabetes in light of any new
information available since the NDDG re-
port. An overriding goal of the committee
was to make the FPG concentration and
the 2-h glucose concentration on the
OGTT equivalent for the diagnosis of di-
abetes,thatis,ifonecriterionwasmet,the
other would likely be met as well (15,16).
With the NDDG criteria, ;95% of pa-
tients whose FPG concentrations were
140 mg/dL had 2-h glucose concentra-
tions $200 mg/dL on the OGTT (17),
but only one-quarter to one-half of pa-
tients with 2-h values on the OGTT
$200 mg/dL had FPG concentrations
$140 mg/dL (17–19). The Expert Com-
mittee decided to retain the 2-h glucose
concentration of $200 mg/dL as a diag-
nostic criterion because changing it
“would be very disruptive” considering
thelargenumberofepidemiologicalstud-
ies using that value to deﬁne diabetes
(15).
The FPG concentration that gave a
prevalenceofdiabetesequivalenttothe2-h
value of $200 mg/dL on an OGTT was
;126 mg/dL (7.0 mmol/L) (5,15,20,21)
and was selected by the Expert Commit-
tee (15). They sought to justify the new
lowered FPG criterion of $126 mg/dL for
the diagnosis of diabetes by linking levels
of glycemia with diabetic retinopathy in
populations of Pima Indians (n 5 960)
(5), Egyptians (n 5 1,081) (22), and a
randomly selected cohort in the Third
National Health and Nutrition Examina-
tion Survey (NHANES III) (n 5 2,821)
(15). FPG, 2-h OGTT glucose, and A1C
levels were divided into deciles and plot-
ted against the prevalence of retinopathy
in each decile. The values reported by the
Expert Committee (15) for the ﬁrst decile
with an increase in retinopathy in the
three studies were, respectively, as fol-
lows: FPG 136, 130, and 120 mg/dL;
2-h glucose 244, 218, and 195 mg/dL;
and A1C 6.7, 6.9, and 6.2%. These values
are very misleading, however, because
they were the lowest glycemic level of
each initial decile in which the prevalence
of retinopathy increased. Although the in-
dividual values of these patients with
retinopathywereunknown,itisextremely
unlikely that most of them congregated at
the lower end of the decile. Using the val-
ues at the bottom of the decile for diagno-
sis certainly increases the sensitivity of the
glucose criteria but at the usual expense of
decreasing the speciﬁcity. Unfortunately,
the lowest values of these deciles have
been used to support the current glucose
criteria for the diagnosis of diabetes
(23,24). It is much more likely that the
mean/medianglycemicvaluesofthedecile
more truly represent the patients with
retinopathy. These mid-decile values
(25) were, respectively: FPG 167, 155,
and 165 mg/dL; 2-h glucose 298, 252,
and 292 mg/dL; and A1C 7.8, 7.5, and
7.4%. Thus, since most people agree that
the microvascular complication of reti-
nopathy is the basis upon which glucose
criteria for the diagnosis of diabetes should
be chosen, the diagnosis in many individ-
uals using the current glucose criteria are
false-positives.
Further evidence that the present
glucose criteria are too low if retinopathy
is used to identify the glycemic levels by
whichtodiagnosediabetesistherelation-
ship among the microvascular complica-
tions of diabetes, glucose concentrations,
and A1C levels. Five longitudinal studies
in over 2,000 diabetic patients followed
from 4 to 9 years demonstrated very little
development or progression of diabetic
retinopathy or nephropathy if the average
A1C levels were maintained between 6
and 7% and none if they were kept in the
normal range below 6% (26–30). Yet, if
the current glucose criteria are used,
many people who are diagnosed with di-
abetes have normal A1C levels. For in-
stance, in the NHANES III population
with no history of diabetes, 61% and
19% of those with FPG concentrations
of 126–139 mg/dL and $140 mg/dL,
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those with 2-h glucose concentrations
on an OGTT of 200–239 mg/dL and
$240 mg/dL, respectively (31), had nor-
mal A1C levels. Given that bona ﬁde di-
abetic retinopathy is not seen in people
with normal A1C levels (5,15,22,23,32),
do we really want to diagnose diabetes in
such individuals?
In contrast to the three studies
(5,15,22) allegedly supporting the cur-
rent glucose criteria, three subsequent
ones (33) could not conﬁrm threshold
values for FPG or 2-h glucose concentra-
tionsonanOGTTforretinopathy.Onthe
other hand, threshold values for A1C lev-
els have been conﬁrmed (23,32).
As already pointed out (1,23), there
are a number of advantages to using A1C
levels to diagnose diabetes, e.g., less var-
iability of the assay compared with glu-
cose, removal of preanalytic modifying
factors, much less day-to-day variability
(,2 % )c o m p a r e dw i t hF P G( 1 2 –15%),
and better reﬂection of long-term gly-
cemia. On the other hand (1,23), there
are potential disadvantages, e.g., interfer-
encebyhemoglobinopathies,inﬂuenceof
iron status (34) and erythrocyte turnover,
and increased levels in African Americans
(35–37) and Latinos (37) independent
of glucose concentrations. These are not
insurmountable barriers. Regarding he-
moglobinopathies, in the 20 different Di-
abetes Control and Complications Trial
(DCCT) aligned assays in use, HbS,
HbC, and HbE interfere with only four
and HbD with only two (38). In the
NHANES 1999–2006 population with-
out known diabetes, mean A1C levels
were equal or 0.1% higher in iron-
deﬁcient women and men, respectively,
comparedwith theiriron-sufﬁcientcoun-
terparts (39). The iron status might be
evaluated in young menstruating women
with A1C levels $6.5% before making
the diagnosis of diabetes. Finally, since
increased glycation is one cause of diabe-
tes complications (40), the slightly higher
A1C levels in minorities might have path-
ological signiﬁcance.
In conclusion, the weakness of the
evidence for the current glucose criteria
to diagnose diabetes strongly supports
Dr. Sacks’ contention based on measure-
ment considerations that if A1C assays
aligned with the DCCT assay (38) are
available,thediagnosisofdiabetesshould
be made by A1C levels $6.5% (24). In
addition to the measurement issues, the
rationale for this conclusion is that 1)t h e
distribution of glucose concentrations in
mostpopulationsisunimodalwithnocon-
sistent cut point with which to diagnose
diabetes; 2)b o n a - ﬁde retinopathy, a spe-
ciﬁc complication of diabetes, is not seen
in people whose A1C levels are ,6.5%
(23,32); 3) raised A1C levels cause the mi-
crovascular complications of diabetes, and
loweringlevelsisbeneﬁcial(26,27,41);and
4) increased glycation of proteins is one
of the causes of diabetes complications,
supplyingadirectlinkbetweenthediagno-
sis and the complications (40). If a DCCT-
aligned A1C assay is not available, glucose
criteria can be used to diagnose diabetes.
Conﬁrmation of diagnostic values should
utilize the same test to avoid confusion
whereby individuals have diabetes by one
criterion but not by another.
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